Daily Alpha · YouTube
· Premarket Alpha · by Buzzberg Research
Who was talking 39 videos · 10 channels
AI capex / financing
2 videos · 1h 32mBloomberg and The David Lin Report frame the tech selloff as a cash-flow and funding test, with AI capex returns, leverage and credit conditions now the swing factor rather than demand.
Tech selloff deepens as SK Hynix scraps Solidigm US IPO
Bloomberg Markets reported a sharp rotation out of technology shares as investors questioned whether AI infrastructure spending can convert into near-term cash flow, with the Nasdaq-100 leading losses and money moving into sovereign bonds and the yen. SK Hynix abandoned its review of a US listing for Solidigm, adding a governance and financing overhang to Korean and Japanese semiconductor names.
+6 more
SEMICONDUCTORS — · 000660.KS +4.7% · 005930.KS +0.5% · FXI -0.3% · TLT -0.3% · IGIB -0.2%Strong earnings aren't rescuing AI infrastructure stocks
The David Lin Report argued the market is moving from rewarding AI expansion to testing whether growth is profitable and financeable; heavy infrastructure spending, weak free cash flow and reliance on external financing are now penalties. Credit conditions and project execution are the key swing factors for the AI chain.
Oil / Middle East
1 video · 1mBrent is set for a third weekly gain as strikes hit Saudi energy sites; Hormuz flows are near prewar levels, so the premium is escalation risk.
Brent set for third weekly gain as Saudi energy sites are hit
Bloomberg reported Brent on track for a third consecutive weekly advance after drone and missile strikes hit targets inside Saudi Arabia, including an airport in the Eastern Province and an Aramco site, while Aramco's Dhahran headquarters told staff to work remotely. Crude flows through Hormuz have largely normalized, so the price strength appears to reflect anticipated escalation risk rather than an actual loss of barrels.
Healthcare
1 video · 5mMizuho's Holz says Moderna's drop reflects a high bar, prefers Merck, and is cautious on healthcare after a fund-flow rally.
Mizuho says Moderna's drop reflects a high bar, not bad data
Mizuho healthcare specialist Jared Holz argued Moderna's sharp post-data decline reflected elevated expectations and a rich valuation rather than weak trial results, framed the cancer-vaccine race as mainly Moderna versus Merck with BioNTech lagging, and said he is cautious on healthcare after a rapid fund-flow-driven rally.
Meta's Class C stock is control-preserving liquidity, not dilution
TBPN framed Meta's plan to issue non-voting Class C shares as a way for Zuckerberg to monetize part of his stake while preserving voting control, calling it economically rational but governance-sensitive. The hosts also flagged Apple's iPhone Duo launch as poorly executed, with unoptimized third-party apps and software polish issues.